X

Drug Profile

Olcegepant

Alternative Names: BIBN 4096; BIBN 4096BS

Latest Information Update: 24 Sep 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Boehringer Ingelheim
Class Antimigraines; Dipeptides; Quinazolines; Small molecules
Mechanism of Action Calcitonin gene-related peptide receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Migraine

Most Recent Events

07 Nov 2007 Pharmacodynamics data from an in vivo study presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
08 Nov 2004 A clinical study has been added to the pharmacokinetics section
13 Oct 2004 A clinical study has been added to the pharmacokinetics section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com